Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Nyse  >  Johnson & Johnson    JNJ

Delayed Quote. Delayed  - 08/24 10:01:36 pm
118.71 USD   -0.61%
08/22 FOR U.S. MEDIA : Janssen Announces 25 Presentations at Upcoming ESC..
08/21 JOHNSON & JOHNS : With B.good, healthy eating comes to King of Pruss..
08/21 JOHNSON & JOHNS : Going from big pharma to farm-fresh
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector news 

Johnson & Johnson : J&J Chairman Weldon's Salary Cut To $1 Million After Stepping Down As CEO

share with twitter share with LinkedIn share with facebook
share via e-mail
0
05/07/2012 | 11:51pm CEST
   By Peter Loftus 
   Of  
 

Johnson & Johnson (JNJ) Chairman William Weldon's annual base salary was reduced by nearly half to $1 million after he stepped down as chief executive last month, the company said Monday.

Weldon's previous annual base salary was set at $1.97 million for 2012, for his roles as both chairman and CEO, but with the expectation that J&J's board would consider the appropriate compensation for Weldon in his role as chairman only.

The decrease reflects that Weldon is no longer CEO, said spokesman Al Wasilewski.

On April 26, Alex Gorsky succeeded Weldon as CEO. Weldon is continuing as chairman and will remain an employee of the company, J&J said in a quarterly report filed with the Securities and Exchange Commission Monday.

J&J said in a previous SEC filing that in his role as chairman, Weldon will work closely with Gorsky to ensure a seamless leadership transition. During this time, all day-to-day management and operational responsibilities are being transferred to Gorsky.

Weldon will remain an employee but not a member of the J&J executive committee, which is the principal management group responsible for strategic operations and allocations of the resources of the company.

Weldon's main duties as chairman will include working with the board of directors, facilitating communication between the board and management, assisting Gorsky in business planning and strategy, representing the company before governmental and other organizations, and serving as chairman of the board's finance committee.

-By Peter Loftus, Dow Jones Newswires; +1-215-982-5581; peter.loftus@dowjones.com

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on JOHNSON & JOHNSON
08/22 FOR U.S. MEDIA ONLY : Janssen Announces 25 Presentations at Upcoming ESC Congres..
08/21 JOHNSON & JOHNSON : With B.good, healthy eating comes to King of Prussia
08/21 JOHNSON & JOHNSON : Going from big pharma to farm-fresh
08/19 JOHNSON & JOHNSON : Diabetes Selfcare Demands Retail, Health Care Collaboration ..
08/19 JOHNSON & JOHNSON : ex-dividend day
08/18 JOHNSON & JOHNSON : Janssen Submits Application to U.S. FDA to Expand Indication..
08/18 JOHNSON & JOHNSON : Frost & Sullivan MindXChange Reveals How Organizations Can L..
08/18 JOHNSON & JOHNSON : Announces Ruling Related to REMICADE in the District of Mass..
08/18 JOHNSON & JOHNSON : Patanjali enters babycare segment
08/17 JOHNSON & JOHNSON : Patent for J&J's Remicade invalidated, cheaper version looms
More news
Sector news : Pharmaceuticals - NEC
08/24DJPFIZER : Buys Part of AstraZeneca's Antibiotics Business -- 2nd Update
08/24DJASTRAZENECA : Sells Part of its Antibiotics Business to Pfizer -- Update
08/24DJPfizer Buys Part of AstraZeneca's Antibiotics Business
08/24DJASTRAZENECA : Sells Part of Antibiotics Business to Pfizer for Up to $1.575 Bill..
08/23DJU.S. Lawmakers Plan Hearing Over Wave of Agriculture Mergers
More sector news : Pharmaceuticals - NEC
News from SeekingAlpha
08/24 Merck Offers Value, Yield, And Reliable Dividends
08/24 How Dividend Growth Investors Can Prosper Even If Interest Rates Increase
08/24 Build A Profitable Dividend Growth Investing Portfolio From Scratch (Podcast ..
08/24 PFIZER-MEDIVATION DEAL : Good Or Bad For Shareholders?
08/24 When Can Portola's Drug Be Approved, And How Much Does It Matter?
Advertisement
Financials ($)
Sales 2016 72 068 M
EBIT 2016 21 808 M
Net income 2016 16 515 M
Finance 2016 13 074 M
Yield 2016 2,64%
P/E ratio 2016 20,21
P/E ratio 2017 17,85
EV / Sales 2016 4,33x
EV / Sales 2017 4,04x
Capitalization 324 776 M
More Financials
Chart JOHNSON & JOHNSON
Duration : Period :
Johnson & Johnson Technical Analysis Chart | JNJ | US4781601046 | 4-Traders
Full-screen chart
Technical analysis trends JOHNSON & JOHNSON
Short TermMid-TermLong Term
TrendsBearishBullishBullish
Technical analysis
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 23
Average target price 127 $
Spread / Average Target 6,7%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Alex Gorsky Chairman & Chief Executive Officer
Dominic J. Caruso Chief Financial Officer & Vice President
Paulus Stoffels Chief Scientific Officer
Susan L. Lindquist Independent Director
Charles O. Prince Independent Director
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
JOHNSON & JOHNSON15.57%324 776
ROCHE HOLDING LTD.-11.47%217 652
NOVARTIS AG-9.45%213 882
PFIZER INC.7.87%211 206
MERCK & CO., INC.18.76%173 462
GLAXOSMITHKLINE PLC21.19%106 958
More Results